Feedback
Settings

Settings

Goto Application

1. WO2017055860 - ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY

PermaLink
Publication Number WO/2017/055860
Publication Date 06.04.2017
International Application No. PCT/GB2016/053042
International Filing Date 29.09.2016
IPC
C07D 403/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 405/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
C07F 9/572 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
553having one nitrogen atom as the only ring hetero atom
572Five-membered rings
C07B 59/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
59Introduction of isotopes of elements into organic compounds
C07D 403/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/4035
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
4035Isoindoles, e.g. phthalimide
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07B 2200/05
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
05Isotopically modified compounds, e.g. labelled
C07D 209/48
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02condensed with one carbocyclic ring
44Iso-indoles; Hydrogenated iso-indoles
48with oxygen atoms in positions 1 and 3, e.g. phthalimide
Applicants
  • ASTEX THERAPEUTICS LIMITED [GB]/[GB]
  • CANCER RESEARCH TECHNOLOGY LIMITED [GB]/[GB]
Inventors
  • CHESSARI, Gianni
  • HOWARD, Steven
  • BUCK, Ildiko Maria
  • CONS, Benjamin David
  • JOHNSON, Christopher Norbert
  • HOLVEY, Rhian Sara
  • REES, David Charles
  • ST. DENIS, Jeffrey David
  • TAMANINI, Emiliano
  • GOLDING, Bernard Thomas
  • HARDCASTLE, Ian Robert
  • CANO, Celine Florence
  • MILLER, Duncan Charles
  • CULLY, Sarah
  • NOBLE, Martin Edward Mäntylä
  • GRIFFIN, Roger John
  • OSBORNE, James Daniel
  • PEACH, Joanne
  • LEWIS, Arwel
  • HIRST, Kim Louise
  • WHITTAKER, Benjamin Paul
  • WATSON, David Wyn
  • MITCHELL, Dale Robert
Agents
  • COOKE, Richard
Priority Data
1517217.429.09.2015GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY
(FR) INHIBITEURS ISOINDOLINONE DE L'INTERACTION MDM2-P53 AYANT UNE ACTIVITÉ ANTICANCÉREUSE
front page image
Abstract
(EN) The invention provides a compound of formula (I): (I) or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
(FR) L'invention concerne un composé de formule (I) : (I) ou un tautomère ou un solvate ou un sel pharmaceutiquement acceptable de celui-ci, les divers substituants étant tels que définis dans les revendications. L'invention concerne également des compositions pharmaceutiques contenant les composés de formule (I), des procédés de fabrication des composés et les utilisations médicales des composés.
Related patent documents
MYPI 2018701138
SG10201912833X
AU2016330030
CA2999400
EP3356350
CN108290871
KR1020180081706
PH1/2018/500610
ID2018/10636
BR112018005932
US20190016708
JP2018534253
VN1201801824
TH1801001808A
NZ780787
DK3356350
PT3356350
LT3356350
CN115572252
FIEP3356350
PL3356350
ES2934181
NZ740737
IL258213
SG11201802279UThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
IN201847010345
MX2018004008
SA518391218This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
RU2018109755This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
US20200247789
US20210276984
AU2021202962
JP2022070998
Latest bibliographic data on file with the International Bureau
# -